Table of Contents
In this issue of Blood, Pagel and colleagues compare pretargeted versus conventional radioimmunotherapy in lymphoma models, reporting the superiority of pretargeting and lack of benefit for antibody cocktails versus a single antibody.
In this issue of Blood, Karp and colleagues describe preclinical and clinical effects of the combination of tipifarnib with etoposide. The study represents an admirable example of successful translation of in vitro data to a phase 1 clinical trial.
Blood group antigens can have critical functions beyond the red blood cell. In this issue of Blood, Lund and colleagues demonstrate a role for Pk in HIV entry, providing biologic insight, identifying potential therapeutic target motifs and expanding the intersections of hematology, transfusion medicine, and infectious disease.
Two mechanisms for targeting tumor vasculature are well recognized: antiangiogenesis and vascular disruption. In this issue of Blood, Bieker and colleagues take therapeutic advantage of coagulation and add a third mechanism, vascular infarction, to this group by demonstrating the effect through first-in-man administration of tTF-NGR.
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference
CLINICAL TRIALS AND OBSERVATIONS
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Clinical Trials & Observations
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide
Clinical Trials & Observations
HEMATOPOIESIS AND STEM CELLS
Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies
Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
The NF-κB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
Targeted deletion of tumor suppressor PTEN augments neutrophil function and enhances host defense in neutropenia-associated pneumonia
PLATELETS AND THROMBOPOIESIS
The tyrosine phosphatase CD148 is an essential positive regulator of platelet activation and thrombosis
RED CELLS, IRON, AND ERYTHROPOIESIS
THROMBOSIS AND HEMOSTASIS
Infarction of tumor vessels by NGR-peptide–directed targeting of tissue factor: experimental results and first-in-man experience
The Rab27a effector MyRIP is recruited to the Weibel-Palade bodies within endothelial cells where it acts as a brake on secretion. At high levels of overexpression MyRIP starts to decorate actin, consistent with providing a link between these VWF-containing secretory granules and the cytoskeleton. The cover shows a confocal image of an endothelial cell overexpressing MyRIP-GFP (yellow) with actin (red) and VWF (blue). See the article by Nightingale et al on page 5010.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board